Predict Parkinson progression with scan
- Trial ID
- NCT07380204
- Official Title
- In Vivo Quantification of Hsp90 in the Human Brain in Healthy Aging and Neurodegeneration Using the Novel PET Radioligand [11C]HSP990
- Goal
- Predict Parkinson progression with scan
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Study Type
- INTERVENTIONAL
- Enrollment
- 48 participants
- Conditions
- Parkinson's Disease (PD), Alzheimer's Disease (AD), Amyotrophic Lateral Sclerosis (ALS)
- Interventions
- [11C]HSP990 PET dosimetry, [11C]HSP990 PET test-retest, [11C]HSP990 simplified scan protocol
Plain-Language Summary
The goal is to map and measure Hsp90, a cellular "chaperone" protein that helps fold and clear damaged proteins, in the brains of people with Parkinson's, Alzheimer's, ALS, and healthy aging to learn how Hsp90 changes with neurodegeneration. The approach uses PET imaging with a new radioligand called [11C]HSP990 that binds Hsp90 so researchers can see where and how much of the protein is present; parts of the study check radiation dose, how reproducible the scans are, and whether the scan can be shortened. This is an imaging test, not a treatment, so it does not alter medications like levodopa. Eligible participants include people with clinically established Parkinson's aged 45 to 85 in Hoehn‑Yahr stages 1,3 with a prior abnormal DaT scan, people meeting diagnostic criteria for AD or ALS, and healthy volunteers roughly 18 to 70 who pass medical and MRI screening and can lie still for the scan.
Locations
- UZ Leuven, Leuven, Vlaam-Brabant, Belgium
Frequently Asked Questions
- What is this trial testing?
- This trial is studying [11C]HSP990 PET dosimetry. The goal is to map and measure Hsp90, a cellular "chaperone" protein that helps fold and clear damaged proteins, in the brains of people with Parkinson's, Alzheimer's, ALS, and healthy aging to learn how Hsp90 changes with neurodegeneration. The approach uses PET imaging with a new radioligand called [11C]HSP990 that binds Hsp90 so researchers can see where and how much of the protein is present; parts of the study check radiation dose, how reproducible the scans are, and whether the scan can be shortened. This is an imaging test, not a treatment, so it does not alter medications like levodopa. Eligible participants include people with clinically established Parkinson's aged 45 to 85 in Hoehn‑Yahr stages 1,3 with a prior abnormal DaT scan, people meeting diagnostic criteria for AD or ALS, and healthy volunteers roughly 18 to 70 who pass medical and MRI screening and can lie still for the scan.
- Who can participate?
- Participants must be between 18 Years and 70 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 3 years and 3 months.